An advanced, highly sensitive and versatile Cypridina luciferase-based HPV pseudovirus system for broad-spectrum neutralization and non-invasive In vivo monitoring - Report - MDSpire
Advertisement
An advanced, highly sensitive and versatile Cypridina luciferase-based HPV pseudovirus system for broad-spectrum neutralization and non-invasive In vivo monitoring
Clinical Report: Cypridina luciferase-Enhanced HPV Pseudovirus System
Overview
This report presents a novel pseudovirus platform utilizing Cypridina luciferase for HPV neutralization assessment. The system demonstrates high sensitivity and eliminates the need for serum heat inactivation, providing a robust tool for evaluating multivalent HPV vaccine candidates.
Background
Human papillomavirus (HPV) is a significant global health threat, primarily causing cervical cancer and other malignancies. Effective prophylactic HPV vaccines are crucial, and the quantification of neutralizing antibodies is essential for vaccine evaluation and epidemiological surveillance. Traditional assays have limitations, necessitating the development of more efficient and sensitive methods.
Data Highlights
The cLuc-PsVs demonstrated robust infectivity with an exceptional correlation (R² > 0.99) with traditional SEAP assays.
Key Findings
The cLuc-PsV platform covers 28 distinct HPV genotypes.
It eliminates the need for thermal inactivation of sera.
Real-time bioluminescence imaging allows non-invasive tracking of mucosal infection.
The platform provides a highly efficient alternative to conventional neutralization assays.
It facilitates both in vitro quantification and in vivo imaging.
Clinical Implications
The cLuc-PsV platform offers a scalable and sensitive method for assessing HPV vaccine efficacy. Its ability to track infections non-invasively may enhance preclinical vaccine screening processes.
Conclusion
The development of the cLuc-PsV system represents a significant advancement in HPV neutralization assays, combining high-throughput capabilities with real-time monitoring.
